The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Celiac Disease (CD)- Market Insights, Epidemiology and Market Forecast-2023-EU5” report provides an overview of the disease and global market size of the Celiac Disease for the EU5 countries (France, Germany, Italy, Spain and UK)). It also includes historical and forecasted epidemiological data for the total prevalent and diagnosed prevalent cases of Celiac Disease in EU5 from 2013-2023.
Celiac disease is a genetic autoimmune disease where
the indigestion of gluten leads to damage in the
small intestine. The number of ways
celiac disease can affect patients, combined with a
lack of training in medical schools and primary
care residency programs, contributes to the poor
diagnosis rate. Currently it is estimated that 80%
of the celiac disease population remains undiagnosed.
Prevalence in Western Europe ranges between 1 in 133. It is higher in relatives of people with celiac disease. Women are affected more commonly than men, but there is no age predilection. This report forecasts predict that the total prevalent cases of Celiac Disease in EU5 is expected to accentuate up to 3.2 Million by 2023 at a Compound Annual Growth Rate (CAGR) of 2.21% from 2013-2023, while the diagnosed prevalent population of Celiac Disease shall grow at a CAGR of 2.86% for the forecast period (2013-2023).
There is no targeted therapy approved for celiac disease. The current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases. Owing to the expected launch of Larazotide Acetate (Innovate Pharmaceuticals) in 2021 followed by the launch of Latiglutenase
(ImmunogenX/Abbvie) in 2023, shall lead to a hike
in the otherwise stable,market size of celiac disease.
estimates suggest that the EU5 market size
is expected to grow at a CAGR of 49.3%
Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
It focuses on the detailed historical and forecasted number of total prevalent cases as well as diagnosed prevalent cases of Celiac Disease for EU5 countries from 2013-2023.
It provides the information of available marketed therapies, including off-label biologics, patent and exclusivity details.
The report also focuses on the details of pipeline
drugs in the pivotal stage of development
including their SWOT Analysis and expected
launch date, which shall help to predict the
impact of those drugs on the market size in
the near future.
Celiac Disease Overview
Celiac Disease Types
Non-Responsive or Refractory CD
Treatment of Celiac Disease
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
LinkedIn :Bharat Book Bureau